Takayuki Kobayashi

Ariake, 1358550, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor-positive, HER2-negative metastatic breast cancer.

Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor-positive, HER2-negative metastatic breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: July 02, 2026

CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy.

CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy.

Journal: Journal of bone oncology

Published: January 07, 2026

Predicting Radiation-Induced Esophagitis in Locally Advanced NSCLC Using Baseline Clinical Factors: A Model From the Japan Lung Cancer Society Integrated Phase II-III Database.

Predicting Radiation-Induced Esophagitis in Locally Advanced NSCLC Using Baseline Clinical Factors: A Model From the Japan Lung Cancer Society Integrated Phase II-III Database.

Journal: Clinical lung cancer

Published: December 10, 2025

Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapy.

Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapy.

Journal: Breast disease

Published: December 05, 2025

Capturing durable benefits: interpreting six-year treatment-free survival and restricted mean survival time in CheckMate 227.

Capturing durable benefits: interpreting six-year treatment-free survival and restricted mean survival time in CheckMate 227.

Journal: Journal of thoracic disease

Published: October 13, 2025

Managing dual primary liver metastases from breast and colorectal cancers.

Managing dual primary liver metastases from breast and colorectal cancers.

Journal: Clinical journal of gastroenterology

Published: July 18, 2025

Corrigendum to 'Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC' [JTO Clinical and Research Reports, Volume 5 Issue 4 (2024) 100659].

Corrigendum to 'Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC' [JTO Clinical and Research Reports, Volume 5 Issue 4 (2024) 100659].

Journal: JTO clinical and research reports

Published: January 06, 2025

Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer.

Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer.

Journal: Endocrine-related cancer

Published: December 26, 2024

Clinical outcomes of patients with EGFR-mutated NSCLC developing interstitial lung disease during first-line osimertinib therapy: a sub-analysis of the Reiwa study.

Clinical outcomes of patients with EGFR-mutated NSCLC developing interstitial lung disease during first-line osimertinib therapy: a sub-analysis of the Reiwa study.

Journal: Japanese journal of clinical oncology

Published: October 27, 2024

Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study.

Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study.

Journal: Breast cancer (Tokyo, Japan)

Published: September 17, 2024

Extra-Articular Stabilization for the Treatment of Recurrent Sternoclavicular Joint Instability: A Report of Two Cases.

Extra-Articular Stabilization for the Treatment of Recurrent Sternoclavicular Joint Instability: A Report of Two Cases.

Journal: JBJS case connector

Published: April 26, 2024

Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer.

Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer.

Journal: BMC cancer

Published: March 16, 2024

Showing 1-12 of 40

Last Updated: 09/26/2026